ATOM is the only active Phase 3 trial for adjuvant treatment of uveal melanoma The trial will assess whether adjuvant treatment with tebentafusp can decrease the risk of relapse, compared to ...

Researchers identified 13 plasma proteins linked to brain aging, uncovering dynamic patterns and biomarkers for early ...

Assembly Speaker Craig Coughlin told Democratic incumbents to put their faces on lawn signs to become more recognizable to ...

Researchers sought to determine whether it would be beneficial to add inotuzumab to the CALGB 10403 pediatric regimen in the treatment of young adults with CD22-positive B-ALL.

FDA recommends that Clene leverage additional Neurofilament Light (NfL) data from its three Expanded Access Protocols (EAPs) and the HEALEY ALS ...

New data from three oral presentations, which demonstrated significant clinical benefit with Sarclisa-based quadruplets in newly diagnosed multiple myeloma (NDMM) patients were featured at the 66th ...

ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patientsNew analysis from the IMROZ phase 3 ...

The authors discuss multiple challenges to the production of policy-relevant results from evaluation of Medicare accountable ...

Patients with newly diagnosed multiple myeloma experienced robust clinical activity when treated with Tecvayli (teclistamab) ...

Ten years after its first FDA approval, Amgen’s Blincyto continues to make inroads in treating acute lymphoblastic leukemia. | Investigators halted study randomization early based on the strong ...

Meta: Blinatumomab plus chemotherapy, vs chemotherapy alone, significantly improved DFS rates and was well tolerated in ...

One of the study’s bright spots is that Hispanic children, who have higher rates of B-cell acute lymphoblastic leukemia and ...